These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35217280)

  • 41. Resolution of tinea pedis with imiquimod cream 5% in a patient with nodular basal cell carcinoma.
    Stashower ME
    Cutis; 2006 Jul; 78(1):66-9. PubMed ID: 16903324
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Imiquimod-responsive basal cell carcinomas and factor XIIIa-enriched dendrocytes.
    Quatresooz P; Piérard GE
    Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():27-9. PubMed ID: 14616809
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma.
    Arits AH; Spoorenberg E; Mosterd K; Nelemans P; Kelleners-Smeets NW; Essers BA
    Br J Dermatol; 2014 Dec; 171(6):1501-7. PubMed ID: 24749843
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nonsyndromic multiple basal cell carcinomas successfully treated with imiquimod 5% cream.
    Kocabaş E; Ermertcan AT; Bilaç C; Bilaç DB; Temiz P
    Cutan Ocul Toxicol; 2010 Dec; 29(4):300-2. PubMed ID: 20684662
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multiple superficial basal cell carcinomata--topical imiquimod versus curette and cryotherapy.
    Dixon AJ
    Aust Fam Physician; 2005; 34(1-2):49-52. PubMed ID: 15727358
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Conventional and combination topical photodynamic therapy for basal cell carcinoma: systematic review and meta-analysis.
    Collier NJ; Haylett AK; Wong TH; Morton CA; Ibbotson SH; McKenna KE; Mallipeddi R; Moseley H; Seukeran D; Ward KA; Mohd Mustapa MF; Exton LS; Green AC; Rhodes LE
    Br J Dermatol; 2018 Dec; 179(6):1277-1296. PubMed ID: 29889302
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Imiquimod in the treatment of eyelid basal cell carcinoma.
    Leppälä J; Kaarniranta K; Uusitalo H; Kontkanen M
    Acta Ophthalmol Scand; 2007 Aug; 85(5):566-8. PubMed ID: 17376190
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma.
    Gowda S; Tillman DK; Fitzpatrick JE; Gaspari AA; Goldenberg G
    J Cutan Pathol; 2009 Aug; 36(8):878-81. PubMed ID: 19586497
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of facial superficial basal cell carcinomas with imiquimod 5% cream.
    Mirza B; De'Ambrosis B
    Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():16-8. PubMed ID: 14616806
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Imiquimod - Its role in the treatment of cutaneous malignancies.
    Bubna AK
    Indian J Pharmacol; 2015; 47(4):354-9. PubMed ID: 26288465
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Imiquimod in basal cell carcinoma: how does it work?
    Dummer R; Urosevic M; Kempf W; Hoek K; Hafner J; Burg G
    Br J Dermatol; 2003 Nov; 149 Suppl 66():57-8. PubMed ID: 14616353
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optical coherence tomography imaging of non-melanoma skin cancer undergoing imiquimod therapy.
    Banzhaf CA; Themstrup L; Ring HC; Mogensen M; Jemec GB
    Skin Res Technol; 2014 May; 20(2):170-6. PubMed ID: 24103017
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of a large superficial basal cell carcinoma with 5% imiquimod: a case report and review of the literature.
    Chen TM; Rosen T; Orengo I
    Dermatol Surg; 2002 Apr; 28(4):344-6. PubMed ID: 11966794
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Psoriasis induced by topical imiquimod.
    Wu JK; Siller G; Strutton G
    Australas J Dermatol; 2004 Feb; 45(1):47-50. PubMed ID: 14961909
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Residual basal cell carcinoma after treatment with imiquimod: a caution on assuming complete cure.
    Harting M; Vujevich J; Goldberg LH
    Dermatol Surg; 2007 Dec; 33(12):1516-9. PubMed ID: 18076623
    [No Abstract]   [Full Text] [Related]  

  • 56. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe.
    Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Tebbs V; Owens M; Stampone P
    Eur J Dermatol; 2005; 15(5):374-81. PubMed ID: 16172048
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vitiligo-like hypopigmentation with poliosis following treatment of superficial basal cell carcinoma with imiquimod.
    Jacob SE; Blyumin M
    Dermatol Surg; 2008 Jun; 34(6):844-5. PubMed ID: 18363730
    [No Abstract]   [Full Text] [Related]  

  • 58. Treatment of Bowen's disease and basal cell carcinoma of the nose with imiquimod 5% cream.
    Wu JK; Siller G; Whitehead K
    Australas J Dermatol; 2003 May; 44(2):123-5. PubMed ID: 12752186
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Imiquimod and lymphatic field clearance: a new hypothesis based on a remote immune action on skin cancer.
    Akkilic-Materna M; Massone C; Komericki P
    Acta Derm Venereol; 2011 Jun; 91(4):432-5. PubMed ID: 21547348
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial.
    de Macedo EM; Carneiro RC; de Lima PP; Silva BG; Matayoshi S
    BMC Ophthalmol; 2015 Apr; 15():35. PubMed ID: 25885553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.